Top Page
Beauty Farm Medical & Health Industry, Inc.
(2373)
Beauty Farm Medical & Health Industry, Inc. (2373) vs. iShares MSCI Hong Kong ETF (EWH)
Beauty Farm Medical & Health Industry, Inc. Business Overview & Revenue Model
Beauty Farm Medical & Health Industry, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.89B | 2.57B | 2.15B | 1.64B | 1.78B | 1.50B |
| Gross Profit | 1.38B | 1.19B | 977.10M | 717.84M | 833.79M | 700.02M |
| EBITDA | 497.57M | 427.49M | 644.82M | 452.43M | 554.51M | 473.71M |
| Net Income | 268.72M | 228.46M | 215.66M | 103.11M | 193.47M | 150.96M |
Balance Sheet | ||||||
| Total Assets | 4.31B | 4.28B | 3.30B | 2.50B | 2.48B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 2.00B | 1.83B | 1.57B | 910.63M | 1.08B | 801.92M |
| Total Debt | 779.08M | 730.59M | 563.12M | 525.50M | 515.46M | 515.69M |
| Total Liabilities | 3.38B | 3.30B | 2.47B | 2.29B | 2.21B | 1.96B |
| Stockholders Equity | 881.02M | 944.64M | 801.90M | 188.75M | 257.36M | 140.87M |
Cash Flow | ||||||
| Free Cash Flow | 1.04B | 682.44M | 466.27M | 241.21M | 536.76M | 613.03M |
| Operating Cash Flow | 984.28M | 796.63M | 625.51M | 382.00M | 669.93M | 680.53M |
| Investing Cash Flow | -394.38M | -340.85M | -711.18M | 53.63M | -385.35M | -368.94M |
| Financing Cash Flow | -325.44M | -223.36M | 133.74M | -432.82M | -271.06M | -273.33M |
Beauty Farm Medical & Health Industry, Inc. Technical Analysis
Beauty Farm Medical & Health Industry, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$6.92B | 23.57 | 31.23% | 2.06% | 28.53% | 22.34% | |
66 Neutral | HK$1.64B | 5.64 | 20.47% | 4.37% | -3.56% | -17.45% | |
66 Neutral | HK$6.61B | 18.11 | 14.86% | 2.54% | 16.41% | 32.97% | |
62 Neutral | HK$8.07B | 16.42 | 6.78% | ― | -13.92% | -36.32% | |
55 Neutral | HK$6.56B | ― | -9.67% | 2.49% | -8.56% | -403.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$66.29M | -0.94 | -51.07% | ― | -20.66% | -77.84% |
Beauty Farm Medical & Health Industry, Inc. Corporate Events
Beauty Farm Medical & Health Industry Inc. announced the acquisition of equity interests in subsidiaries operating under the Naturade brand, with a total consideration of RMB40.0 million. This acquisition will add 19 new direct stores to the company’s portfolio, enhancing its coverage in core cities of the Greater Bay Area and significantly boosting its revenue. The transaction is considered a connected transaction under the Hong Kong Stock Exchange’s Listing Rules but is exempt from certain requirements due to its fair and reasonable terms.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$31.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. has announced an extraordinary general meeting to approve a share purchase agreement for acquiring 100% of Shanghai Siyanli Industrial Co., Ltd. The transaction involves issuing 15,798,147 shares at HK$28.71 each to the vendors, pending approval from the Hong Kong Stock Exchange, which could enhance the company’s market position and expand its operational capabilities.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$31.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. has announced a plan to enhance shareholder value by allocating up to HK$1.2 billion over the next three years for dividends and share repurchases. The company intends to fund these initiatives through internal resources, ensuring no adverse impact on its working capital. The execution of these plans will depend on the company’s performance and market conditions, with no guarantees on timing or amounts.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 40,000 shares, totaling approximately HK$1,236,230, as part of a broader repurchase strategy. The Board believes this move reflects confidence in the company’s long-term value and aims to enhance shareholder returns, although future repurchases depend on market conditions.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry, Inc. announced an increase in shareholding by a non-executive director, Ms. Yi Lin, who purchased 61,000 shares, reflecting her confidence in the company’s future. Additionally, the company conducted an on-market share repurchase of 30,000 shares, indicating management’s belief in the long-term value of the enterprise and aiming to enhance capital market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary share repurchase, acquiring 30,000 shares on October 28, 2025, as part of a broader initiative that has seen the repurchase of 445,000 shares since October 15, 2025. The board believes the current share price undervalues the company’s intrinsic worth and prospects, and the repurchase is intended to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary repurchase of 40,000 shares on October 27, 2025, at an average price of HK$31.10 per share, totaling approximately HK$1,244,090. This move is part of a broader repurchase strategy that has seen 415,000 shares repurchased since October 15, 2025, for a total of HK$13,224,850. The board believes the current trading price undervalues the company’s intrinsic worth and business prospects, and this repurchase reflects confidence in the company’s long-term value, aiming to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, buying back 50,000 shares at an average price of HK$31.72 each, totaling approximately HK$1,585,810. This action is part of a broader repurchase strategy, with a total of 375,000 shares repurchased since October 15, 2025, for about HK$11,980,760. The board believes the current share price undervalues the company’s intrinsic worth and prospects, and the repurchase is expected to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 65,000 shares at an average price of HK$30.33 per share, totaling approximately HK$1,971,240. This move, part of a broader repurchase strategy totaling 325,000 shares, reflects the board’s confidence in the company’s long-term value and aims to enhance shareholder returns by capitalizing on the current undervaluation of its stock.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 50,000 shares for approximately HK$1,565,530. The Board believes the current share price undervalues the company and sees the repurchase as a demonstration of confidence in its long-term value, aiming to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 70,000 shares, totaling approximately HK$2,209,470, as part of a broader repurchase strategy that has seen 210,000 shares bought back since October 15, 2025. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 60,000 shares for approximately HK$1,942,870, reflecting management’s confidence in the company’s long-term value. The board believes the current share price undervalues the company’s prospects, and this repurchase aims to enhance the company’s market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a recent on-market share repurchase, acquiring 30,000 shares for approximately HK$1,011,030. The Board believes the current share price undervalues the company’s intrinsic worth and business prospects, and the repurchase reflects confidence in its long-term value, aiming to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 50,000 shares at an average price of HK$33.90 per share, totaling approximately HK$1,694,810. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns. The repurchase was conducted under a mandate allowing the company to buy back up to 10% of its issued shares.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry, Inc. has announced a major transaction involving the acquisition of 100% of the issued shares in Shanghai Siyanli Industrial for RMB1,250.0 million. This acquisition will result in Shanghai Siyanli Industrial becoming an indirect wholly-owned subsidiary of Beauty Farm, with its results, assets, and liabilities consolidated into the group’s accounts. The transaction involves the issuance of consideration shares, which will be subject to shareholder approval at an Extraordinary General Meeting (EGM). The acquisition is classified as a major transaction under the Listing Rules, necessitating certain reporting and approval requirements. Shareholders and potential investors are advised to exercise caution as the acquisition is subject to conditions precedent and may not proceed.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. announced its interim results for the first half of 2025, showcasing significant growth in key financial metrics. The company reported a 28.2% increase in revenue and a 35.5% rise in net profit compared to the same period in 2024, driven by a substantial increase in client visits and active members at its direct stores. The gross profit margin improved to 49.3%, reflecting enhanced operational efficiency. The company also provided non-HKFRS adjusted net profit figures, highlighting a 37.8% increase, which offers additional insights into its financial performance. These results underscore the company’s strong market positioning and operational success, benefiting shareholders and potential investors.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.